Prostate cancer is the most common cancer in men. Radical prostatectomy (RP) is a common treatment for this cancer, and after surgery, patients are still considered at risk. It’s important to accurately identify high risk patients after RP in order to reduce risk through further treatments. The genomic classifier (GC) DecipherTM, a product of GenomeDx Biosciences, has been developed to predict early metastasis in prostate cancer patients after RP. Validation of the GC has been performed on individual studies. However, there lacks methodology in validating the GC over several studies several studies through joint validation approach. This research project aims to develop methodology that can estimate the common effect of a GC over multiple studies with case-cohort designs through a joint analysis. With this novel methodology, GenomeDx Biosciences can better validate the genomic classifier and thus evaluate its value more efficiently.
Dr. Charmaine Dean
Statistics / Actuarial sciences
Find the perfect opportunity to put your academic skills and knowledge into practice!Find Projects